title: Therapeutic Corneal Transplant for Fungal Keratitis Refractory to Medical Therapy.
abstract: OBJECTIVE
  To report the outcomes of therapeutic corneal transplant for managing fungal keratitis that is refractory to medical treatment.
  
  
  METHODS
  Retrospective data analyses of the medical records was performed on 17 patients who underwent a therapeutic corneal transplant for severe culture-proven fungal keratitis between October 2006 and August 2013. We evaluated demographics, fungal organism type, surgical data, recurrence presentation, disease course, follow-up, and graft status.
  
  
  RESULTS
  Mean patient age was 53.2 years (range, 33-81 y). The male/female ratio was 12/5. All patients had positive microscopic evaluation and positive culture results for fungal infection. The most common fungal agent was Fusarium sp. (35%). Nine patients reported a history of injury to the cornea and/or contact with plant material or soil. The mean best-corrected visual acuity at the initial visit was 2.45 logMAR unit (range, 0.52-3.10 logMAR unit). The mean follow-up was 14 months (range, 6-76 mo). Four patients underwent evisceration surgery because of graft lysis or uncontrolled recurrent disease. Recurrence of the fungal infection after corneal transplant was seen in 8 patients (47.05%). The graft rejection rate was 18.18%. At the final visit, 5 grafts were clear, 4 were translucent, and 2 were opaque. There were 2 phthisis bulbi owing to catastrophic disease. The mean final best-corrected visual acuity was 1.64 logMAR unit (range, 0.22-3.10 logMAR unit).
  
  
  CONCLUSIONS
  Although therapeutic corneal transplant has a higher incidence of infection recurrence and graft failure, it continues to be an effective treatment for uncontrolled, refractory fungal keratitis cases to save the affected eye.
authors.affiliation: >From the Department of Ophthalmology, Ege University, Izmir, Turkey.
authors.forename: Ozlem
authors.initials: O
authors.lastname: Barut Selver
authors.forename: Sait
authors.initials: S
authors.lastname: Egrilmez
authors.forename: Melis
authors.initials: M
authors.lastname: Palamar
authors.forename: Mesut
authors.initials: M
authors.lastname: Arici
authors.forename: Suleyha
authors.initials: S
authors.lastname: Hilmioglu Polat
authors.forename: Ayse
authors.initials: A
authors.lastname: Yagci
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000627:therapeutic use*; D016039:Corneal Transplantation / Q000009:adverse effects; D004351:Drug Resistance; D015821:Eye Infections, Fungal / Q000175:diagnosis / Q000382:microbiology / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D060585:Fusariosis / Q000175:diagnosis / Q000382:microbiology / Q000503:physiopathology / Q000601:surgery*; D005670:Fusarium / Q000302:isolation & purification; D006084:Graft Rejection / Q000209:etiology; D006801:Humans; D007634:Keratitis / Q000175:diagnosis / Q000382:microbiology / Q000503:physiopathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D020127:Recovery of Function; D012008:Recurrence; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D000935:Antifungal Agents